Levels of GLP -1, a hormone that slows food’s movement through the GI tract for healthy digestion, can be too low in people with short bowel syndrome (SBS)--leading to poor nutrient absorption. Our Phase 2 drug is intended to offset missing GLP-1 in SBS: bit.ly/3aij8DW

Recent preclinical data suggest that anti-GIP monoclonal antibodies can reduce body weight without suppressing food intake in mice. We’re developing a humanized anti-GIP monoclonal antibody for the treatment of targeted obesity disorders. Learn more: bit.ly/3D3aveD

Today we announced a business update and reported financial results for the third quarter of 2022. Read our full press release here: bit.ly/3tdverx $NMTR

#DYK #ShortBowelSyndrome (SBS) is a rare syndrome related to poor absorption of nutrients resulting from a significant resection of the small intestine? Learn more about SBS & 9 Meters’ drug candidate in development to treat patients with this disorder: bit.ly/3aij8DW

$NMTR has announced a continued preclinical collaboration agreement w/ renowned cancer center Gustave Roussy using our microbiome modulator candidate to study the relationship between intestinal microbiome composition & responses to cancer treatments: bit.ly/3EvvEjr

Our drug candidate for #ShortBowel syndrome is intended to replace missing GLP-1, a hormone that prevents the #GI tract from moving rapidly, thus normalizing GI transit time and improving intestinal absorption of nutrients and water. Learn more here: bit.ly/3aij8DW

We are incredibly thankful for our team at 9 Meters who work hard every day to develop therapeutics for people with rare or debilitating digestive diseases.

We announced the design of our Phase 3 #ClinicalTrial, VIBRANT 2, to evaluate the efficacy, safety and tolerability of our GLP-1 receptor agonist for adults with #ShortBowel syndrome (SBS). Read the press release for more details: bit.ly/3VCJcPJ

#DYK the average GI tract is ~9 meters? Within those 9 meters, the GI tract has multiple biologic functions that can be harnessed to fight disease. We’re putting the power of gut biology to work to address multiple digestive disease. Learn more: bit.ly/3a3gq4m

We’re developing a potential #microbiome modulator that was found to be effective alone or when combined with #ImmuneCheckpointInhibitors in a pre-clinical study for spontaneous aggressive skin melanoma. Learn more about our pipeline of candidates: bit.ly/3aij8DW

#ICYMI, we announced the design of our Phase 3 study evaluating our drug candidate for #ShortBowel syndrome (SBS). Our team is looking forward to moving one step closer to potentially providing SBS patients with a new treatment option: bit.ly/3VCJcPJ

Our drug candidate for #ShortBowel syndrome (SBS) is designed to counteract the low levels of the hormone GLP-1 seen in SBS. Restoring GLP-1 may slow gut motility & improve intestinal absorption of nutrients and water. Learn more: bit.ly/3aij8DW

Wishing everyone a happy and healthy #HolidaySeason! We’re looking forward to the new year ahead and continuing our mission to help patients with rare and debilitating digestive disorders.

Learn more about Short Bowel Syndrome. Check out the National Organization for Rare Disorders' (NORD) video library for an animated introduction of SBS: lnkd.in/eqRsesbB. #9metersbio #sbs

You're Not Alone. If you or a family member are struggling with Short Bowel Syndrome here are some organizations that can help... #9metersbiopharma

9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference John Temperato, President and Chief Executive Officer of 9 Meters, is scheduled to present. Date: Monday, March 13, 2023 Time: 3:20 PM ET Webcast link: wsw.com/webcast/oppenh…

9 Meters Biopharma to present at the Oppenheimer 33rd Annual Healthcare Conference Updated Presentation Date/Time: Wednesday, March 15 at 10:00 AM ET 9meters.com/events

9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022 feeds.issuerdirect.com/news-release.h…

On April 7, 2023, the World Health Organization (WHO) will mark its 75th anniversary, along with its 194 Member States and other partners, by calling for a renewed drive for health equity.” To learn more about the WHO please visit: who.int/campaigns/75-y…]

In case you missed the recent news. Links feeds.issuerdirect.com/news-release.h… and aspenjournals.onlinelibrary.wiley.com/doi/10.1002/jp…